Game-changing weight loss Jabs can help to ward off a maximum of 14 types of cancer, suggesting world-cenistizing experts.
Mounjaro, Ozempic and other fatty injections have a new era in the war against obesity, but are also linked to other health benefits, such as reducing the risk of heart attacks, strokes and kidney diseases.
Now scientists have discovered that the drugs can reduce the risk of reaching weight -related cancers, including difficult types to be diagnosed, such as pancreas, kidney and ovary.
The breakthrough investigation showed that the Jabs were most effective in specifically cutting down the risk of colon and rectal cancers.
Both have seen a disturbing increases in cases in the 1950s in recent years that doctors all over the world are astonished.
American scientists, who carried out the process, said the findings show that the medicines have a ‘preventive effect’ in people with a higher risk of these 14 diseases.
However, they warned that further research was needed to confirm their findings.
Nor did researchers speculate why the medicines, which are called the class of medicines, GLP-1 agonists, can lower the chances of a patient’s cancer.
Mounjaro, Ozempic and other fat -feeling injections have ushered in a new era in the war against obesity, but are also linked to other health benefits, such as reducing the risk of heart attacks, strokes and kidney disease
Lucas Mavromatis, an expert in obesity at NYU Grossman School of Medicine in New York and the main author of the study, said: ‘Although obesity is now recognized as an increasingly important cause of cancer in the United States and worldwide, it has not been proven that no medicines lower the risk of cancer associated with obesity.
‘Our study is starting to fill that gap by evaluating GLP-1 receptor agonists, a relatively new but generally prescribed medication that treats diabetes, obesity and related disorders.
‘Our results suggest that they can reduce the chance of developing certain cancers – especially cancers of the colon and rectum – and reduce the death vessels as a result of all causes.
“This data is reassuring, but more studies are needed to prove the connection.”
In the study, researchers studied data of more than 170,000 obese patients with diabetes, on average 57 years old.
During a follow-up of a decade, they compared the cancer risk in patients on GLP-1 agonists against patients with DDP-4 inhibitors, a different diabetes medication.
The 14 rated cancers include esophageal, Colon, rectum, stomach, liver, gallbladder, pancreas, kidney and postmenopausal chest.
Ovarian, endometrium and thyroid gland, as well as multiple myeloma and meningiomas, were the others.
They discovered that on GLP-1’s had a 7 percent lower risk of developing an obesity-related cancer than patients with DDP-4 inhibitors.
When other health benefits were processed, these patients were also 8 percent less likely to die during the 10 -year period.
In general, the largest reduction was seen for colon (16 percent) and rectale (28 percent) cancers.
These benefits were greater in women compared to men, where obese women on GLP-1’s registered an 8 percent lower risk of obesity-related cancer and 20 percent lower risk of all causes of death compared to women treated with DDP-4 inhibitors.
The findings will be fully presented next week on the American Society for Clinical Oncology (ASCO) Conference in Chicago.
Dr. Robin Zon, Asco President, said: ‘This study increases an intriguing hypothesis: that the ever-popular GLP-1 drugs are used to treat diabetes and obesity can offer some benefits to reduce the risk of developing cancer.
‘I see many patients with obesity, and given the clear link between cancer and obesity, it is important to define the clinical role of GLP-1 drugs in cancer prevention.
‘Although this study does not establish a causal link, it refers that these medicines can have a preventive effect.
Colon cancer can ensure that you have blood in your shit, a change in intestinal habit, a lump in your intestine that can cause obstructions. Some people also suffer from weight loss due to these symptoms
“Future research is needed to validate these findings, even in patients who don’t have diabetes.”
The priks were Originally developed as a diabetes treatment, but has become one of the world’s most common drugs for weight loss in recent years, with a large number of celebrities inclusive Elon Musk and Boris Johnson-where they make it in an attempt to descend.
It is thought that at least half a million NHS patients and about 15 million in the US are now thought that they use weight loss Jabs, which can help patients to lose up to 20 percent of their body weight in just a few months.
Obesity itself increases the chances of person who suffers serious health status that can damage the heart, such as high blood pressure, as well as cancers.
About two in three adults in the UK are obese or overweight, giving the country one of the highest obesity rates in Europe. In the US the figure is almost 75 percent.
#Shocking #link #discovered #Ozempic #Cancer